Related Experiment Video

Updated: Feb 8, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Sacubitril/Valsartan: potential treatment for paediatric heart failure

Bibhuti B Das1, Frank Scholl1, Breanna Vandale1

  • 1Joe DiMaggio Children's Hospital Heart Institute,Memorial Health Care,Hollywood,FL,USA.

Cardiology in the Young
|July 7, 2018
PubMed

Insights

Sacubitril/Valsartan significantly reduces mortality and hospitalizations in adults with heart failure compared to enalapril. Its potential benefits in pediatric heart failure patients require further investigation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Pediatrics

Background:

  • Heart failure affects both adults and children, but treatment approaches may differ.
  • Sacubitril/Valsartan has shown significant benefits in adult heart failure patients.
  • The efficacy of Sacubitril/Valsartan in pediatric heart failure remains unestablished.

Purpose of the Study:

  • To review the pathophysiology of heart failure in children versus adults.
  • To explore the potential role and benefits of Sacubitril/Valsartan in pediatric heart failure.

Main Methods:

  • Review of existing literature on heart failure pathophysiology in different age groups.
  • Analysis of clinical trial data for Sacubitril/Valsartan in adults.
  • Discussion of potential mechanisms for Sacubitril/Valsartan in pediatric populations.

Main Results:

  • Sacubitril/Valsartan demonstrated superiority over enalapril in reducing global mortality and morbidity in adults with heart failure.
  • The combination therapy reduced sudden cardiac death, death from worsening heart failure, hospitalizations, and disease progression in adults.

Conclusions:

  • Sacubitril/Valsartan is a promising therapeutic option for adult heart failure.
  • Further research is warranted to determine the safety and efficacy of Sacubitril/Valsartan in pediatric heart failure patients.

Keywords:
Paediatric heart failureangiotensin receptor blockerneprilysin inhibitor

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
975
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
924
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342